.

Pharmaceutical Business Intelligence

  • Anticipate P&T budget requirements
  • Evaluate market entry opportunities
  • Find generic sources and suppliers
  • Predict branded drug patent expiration

► Plans and Pricing

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

DrugPatentWatch Database Preview

Claims for Patent: 8,252,307

« Back to Dashboard

Claims for Patent: 8,252,307

Title:Method for treating and/or preventing retinal diseases with sustained release corticosteroids
Abstract: The present invention relates to a method for administering a corticosteroid to a posterior segment of an eye. In the method, a sustained release device is implanted to deliver the corticosteroid to the eye. The aqueous corticosteroid concentration remains less than vitreous corticosteroid concentration during release of the corticosteroid from the device.
Inventor(s): Ashton; Paul (Newton, MA)
Assignee: pSivida US, Inc. (Watertown, MA)
Application Number:12/684,341
Patent Claims: 1. A sustained release device including fluocinolone acetonide (FA) disposed therein as the sole active agent, which device is dimensioned for implantation in the vitreal cavity of a patient's eye and configured to have a release rate over a time course of at least 4 weeks after implantation, which release rate results in an aqueous humor FA concentration less than one tenth the vitreous FA concentration.

2. A sustained release device including FA disposed therein as the sole active agent, which device is dimensioned for implantation in the vitreal cavity of a patient's eye and configured to have a release rate for said FA to produce a sustained and therapeutic concentration of said FA over a time course of at least 4 weeks effective for reducing neovascularization, edema, diabetic retinopathy, retinal detachment, sickle cell retinopathy, senile macular degeneration, retinal neovascularization, subretinal neovascularization, chronic posterior and pan uveitis, neovascularization resulting following a combined vitrectomy and lensectomy, vascular diseases retinal ischemia, choroidal vascular insufficiency, choroidal thrombosis, neovascularization of the optic nerve, diabetic macular edema, cystoid macular edema, macular edema, retinitis pigmentosa, retinal vein occlusion, proliferative vitreoretinopathy, angioid streak, or neovascularization due to penetration of the eye or ocular injury, which release rate results in an aqueous humor FA concentration which does not cause an increase in intraocular pressure over said time course that could result in damage to a patient's ocular tissue.

3. A sustained release device including FA disposed therein as the sole active agent, which device is dimensioned for implantation in the vitreal cavity of a patient's eye and configured to have a release rate for said FA to produce a sustained and therapeutic concentration of said FA over a time course of at least 4 weeks effective for reducing neovascularization, edema, or diabetic retinopathy, retinal detachment, sickle cell retinopathy, senile macular degeneration, retinal neovascularization, subretinal neovascularization, chronic posterior and pan uveitis, neovascularization resulting following a combined vitrectomy and lensectomy, vascular diseases retinal ischemia, choroidal vascular insufficiency, choroidal thrombosis, neovascularization of the optic nerve, diabetic macular edema, cystoid macular edema, macular edema, retinitis pigmentosa, retinal vein occlusion, proliferative vitreoretinopathy, angioid streak, or neovascularization due to penetration of the eye or ocular injury, which release rate results in an aqueous humor FA concentration less than one tenth the vitreous FA concentration.

4. The device of any of claims 1-3, wherein the aqueous humor FA concentration is less than about 0.05 .mu.g/ml.

5. The device of any of claims 1-3, wherein the FA is released with pseudo zero order kinetics.

6. The device of any of claims 1-3, configured to have a release rate for said FA over said time course.

7. The device of any of claims 1-3, wherein said time course is at least 100 days.

8. The device of claim 1 or 3, which release rate results in an aqueous humor FA concentration which does not cause an increase in intraocular pressure over said time course that could result in damage to a patient's ocular tissue.

9. The device of claim 8, wherein the release rate for said FA over said time course is effective for reducing one or more of senile macular degeneration, chronic posterior or and pan uveitis, or diabetic macular edema.

10. The device of any of claims 1-3, which release rate does not produce ocular steroid-induced toxicity.

11. The device of claim 2 or 3, which device is effective for reducing senile macular degeneration, chronic posterior or pan uveitis, or diabetic macular edema.

12. A sustained release device including a steroid disposed therein as the sole active agent, which device is dimensioned for implantation in the vitreal cavity of a patient's eye and configured to release a therapeutically effective amount of steroid, which amount does not produce ocular or systemic steroid-induced toxicity.

13. A sustained release device including a steroid disposed therein as the sole active agent, which device is dimensioned for implantation in the posterior segment of a patient's eye and configured to release a therapeutically effective amount of steroid, which amount does not produce ocular or systemic steroid-induced toxicity.

14. The device of claim 12 or 13, wherein the steroid is released with pseudo zero order kinetics.

15. A sustained release device including FA disposed therein as the sole active agent, which device is dimensioned for implantation in the posterior segment of a patient's eye and configured to have a release rate over a time course of at least 4 weeks after implantation, which release rate results in an aqueous humor FA concentration less than one tenth the vitreous FA concentration.

16. A sustained release device including FA disposed therein as the sole active agent, which device is dimensioned for implantation in the posterior segment of a patient's eye and configured to have a release rate for said FA to produce a sustained and therapeutic concentration of said FA over a time course of at least 4 weeks effective for reducing neovascularization, edema, diabetic retinopathy, retinal detachment, sickle cell retinopathy, senile macular degeneration, retinal neovascularization, subretinal neovascularization, chronic posterior and pan uveitis, neovascularization resulting following a combined vitrectomy and lensectomy, vascular diseases retinal ischemia, choroidal vascular insufficiency, choroidal thrombosis, neovascularization of the optic nerve, diabetic macular edema, cystoid macular edema, macular edema, retinitis pigmentosa, retinal vein occlusion, proliferative vitreoretinopathy, angioid streak, or neovascularization due to penetration of the eye or ocular injury, which release rate results in an aqueous humor FA concentration which does not cause an increase in intraocular pressure over said time course that could result in damage to a patient's ocular tissue.

17. A sustained release device including FA disposed therein as the sole active agent, which device is dimensioned for implantation in the posterior segment of a patient's eye and configured to have a release rate for said FA to produce a sustained and therapeutic concentration of said FA over a time course of at least 4 weeks effective for reducing neovascularization, edema, diabetic retinopathy, retinal detachment, sickle cell retinopathy, senile macular degeneration, retinal neovascularization, subretinal neovascularization, chronic posterior and pan uveitis, neovascularization resulting following a combined vitrectomy and lensectomy, vascular diseases retinal ischemia, choroidal vascular insufficiency, choroidal thrombosis, neovascularization of the optic nerve, diabetic macular edema, cystoid macular edema, macular edema, retinitis pigmentosa, retinal vein occlusion, proliferative vitreoretinopathy, angioid streak, or neovascularization due to penetration of the eye or ocular injury, which release rate results in an aqueous humor FA concentration less than one tenth the vitreous FA concentration.

18. The device of any of claims 15-17, wherein the aqueous humor FA concentration is less than about 0.05 .mu.g/ml.

19. The device of any of claims 15-17, wherein the FA is released with pseudo zero order kinetics.

20. The device of any of claims 15-17, configured to have a release rate for said FA over said time course.

21. The device of any of claims 15-17, wherein said time course is at least 100 days.

22. The device of claim 15 or 17, which release rate results in an aqueous humor FA concentration which does not cause an increase in intraocular pressure over said time course that could result in damage to a patient's ocular tissue.

23. The device of claim 22, wherein the release rate for said FA over said time course is effective for reducing one or more of senile macular degeneration, chronic posterior or and pan uveitis, or diabetic macular edema.

24. The device of any of claims 15-17, which release rate does not produce ocular steroid-induced toxicity.

25. The device of claim 16 or 17, which device is effective for reducing senile macular degeneration, chronic posterior or pan uveitis, or diabetic macular edema.
« Back to Dashboard

For more information try a trial or see the database preview and plans and pricing

How are People Using DrugPatentWatch?

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

`abc